Inj, lanreotide, (cipla) 1mg
Products billed under this code include Lanreotide.
Payment limit per 1 MG, by effective quarter, 4Q22 to 4Q26. Gaps mean the code was not in that quarter’s file, or CMS gave no payment limit.Products billed under J1932
From the 4Q26 NDC–HCPCS crosswalk. “Limit / pkg” is the 4Q26 payment limit times the billing units in one package.
| Product | Labeler | NDC | Units / pkg | Limit / pkg |
|---|---|---|---|---|
| Lanreotide | Cipla USA, Inc. | 69097-0870-67 | 120 | $2,439.60 |
Every quarter
| Quarter | Payment limit | Change | Billing unit | Description | Source file |
|---|---|---|---|---|---|
| 4Q26 | $20.33 | $0.00 | 1 MG | Inj, lanreotide, (cipla) 1mg | v1, posted September 17, 2026 |
| 3Q26 | $20.33 | −$11.86 | 1 MG | Inj, lanreotide, (cipla) 1mg | v1, posted September 15, 2026 |
| 2Q26 | $32.19 | −$6.027 | 1 MG | Inj, lanreotide, (cipla) 1mg | v1, posted September 15, 2026 |
| 1Q26 | $38.217 | +$8.373 | 1 MG | Inj, lanreotide, (cipla) 1mg | v1, posted September 15, 2026 |
| 4Q25 | $29.844 | +$5.394 | 1 MG | Inj, lanreotide, (cipla) 1mg | v1, posted September 8, 2026 |
| 3Q25 | $24.45 | −$0.972 | 1 MG | Inj, lanreotide, (cipla) 1mg | v1, posted March 10, 2026 |
| 2Q25 | $25.422 | −$5.26 | 1 MG | Inj, lanreotide, (cipla) 1mg | v1, posted March 10, 2026 |
| 1Q25 | $30.682 | −$6.121 | 1 MG | Inj, lanreotide, (cipla) 1mg | v1, posted December 19, 2025 |
| 4Q24 | $36.803 | −$5.54 | 1 MG | Inj, lanreotide, (cipla) 1mg | v1, posted June 11, 2025 |
| 3Q24 | $42.343 | −$1.681 | 1 MG | Inj, lanreotide, (cipla) 1mg | v1, posted June 11, 2025 |
| 2Q24 | $44.024 | −$4.753 | 1 MG | Inj, lanreotide, (cipla) 1mg | v1, posted March 11, 2025 |
| 1Q24 | $48.777 | −$1.194 | 1 MG | Inj, lanreotide, (cipla) 1mg | v1, posted December 19, 2024 |
| 4Q23 | $49.971 | −$1.407 | 1 MG | Inj, lanreotide, (cipla) 1mg | v1, posted October 10, 2024 |
| 3Q23 | $51.378 | −$9.113 | 1 MG | Inj, lanreotide, (cipla) 1mg | v1, posted June 5, 2024 |
| 2Q23 | $60.491 | +$0.113 | 1 MG | Inj, lanreotide, (cipla) 1mg | v1, posted February 23, 2024 |
| 1Q23 | $60.378 | −$0.509 | 1 MG | Inj, lanreotide, (cipla) 1mg | v1, posted December 6, 2023 |
| 4Q22 | $60.887 | – | 1 MG | Inj, lanreotide, (cipla) 1mg | v1, posted June 22, 2023 |
“Change” is the difference from the previous quarter, shown only when both quarters have a payment limit and the billing unit is the same. “vs. last quarter” and “vs. a year ago” follow the same rule.
CMS source files
- 4Q26: 2026-09-17_october-2026-medicare-part-b-payment-limit-files-final.zipposted September 17, 2026
- 4Q26: 2026-09-17_october-2026-ndc-hcpcs-crosswalk-final.zipposted September 17, 2026
- 3Q26: 2026-09-15_july-2026-medicare-part-b-payment-limit-files.zipposted September 15, 2026
- 2Q26: 2026-09-15_april-2026-medicare-part-b-payment-limit-files-final-file.zipposted September 15, 2026
- 1Q26: 2026-09-15_january-2026-medicare-part-b-payment-limit-files.zipposted September 15, 2026
- 4Q25: 2026-09-08_october-2025-asp-pricing-final-file.zipposted September 8, 2026
- 3Q25: 2026-03-10_july-2025-asp-pricing-file.zipposted March 10, 2026
- 2Q25: 2026-03-10_april-2025-asp-pricing-file.zipposted March 10, 2026
- 1Q25: 2025-12-19_january-2025-asp-pricing-file-03-11-25-final-file.zipposted December 19, 2025
- 4Q24: 2025-06-11_october-2024-asp-pricing-file.zipposted June 11, 2025
- 3Q24: 2025-06-11_july-2024-asp-pricing-file.zipposted June 11, 2025
- 2Q24: 2025-03-11_april-2024-asp-pricing-file.zipposted March 11, 2025
- 1Q24: 2024-12-19_january-2024-asp-pricing-file.zipposted December 19, 2024
- 4Q23: 2024-10-10_october-2023-asp-pricing-file.zipposted October 10, 2024
- 3Q23: 2024-06-05_july-2023-asp-pricing-file.zipposted June 5, 2024
- 2Q23: 2024-02-23_april-2023-asp-pricing-file.zipposted February 23, 2024
- 1Q23: 2023-12-06_january-2023-asp-pricing-file.zipposted December 6, 2023
- 4Q22: 2023-06-22_october-2022-asp-pricing-file.zipposted June 22, 2023